A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients

De Novo Kidney Transplantation Clinical Trial

Official title:

Efficacy and Safety of Alefacept in Combination With Tacrolimus, Mycophenolate Mofetil and Steroids in de Novo Kidney Transplantation - a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00617604
• Other study ID #: 0485-CL-E201
• Secondary ID: 2007-002092-14
• Status: Completed
• Phase: Phase 2
• First received: February 6, 2008
• Last updated: January 5, 2016
• Start date: December 2007
• Est. completion date: September 2009

Study information

• Verified date: January 2016
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Agency for Health and Food SafetyBelgium: Federal Agency for Medicinal Products and Health ProductsCzech Republic: State Institute for Drug ControlFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical DevicesHungary: National Institute of PharmacyItaly: Ministry of HealthNetherlands: Medicines Evaluation Board (MEB)Poland: Ministry of HealthSpain: Ministry of HealthSweden: Medical Products AgencyUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether alefacept is effective and well tolerated when used with a combination of tacrolimus, mycophenolate mofetil and steroids versus a combination therapy of placebo, tacrolimus and steroids in the prevention of kidney transplant rejection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 218
• Est. completion date: September 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Subject with end stage kidney disease who is a suitable candidate for primary kidney transplantation or retransplantation

• Male or female subject at least 18 years of age and younger than 65 years

• Subject receiving a kidney transplant from a non-human leucocyte antigen (HLA) identical living donor or deceased HLA identical/non-HLA identical donor between 5 and 59 years of age with compatible ABO blood type (Blood group system A, B, AB and 0)

Exclusion Criteria:

• Subject has a panel reactivity antibody grade > 20% in the previous 6 months and/or had had a previous graft survival shorter than 1 year due to immunological reasons

• Subject received a kidney transplant from a non-heart beating donor

• Subject has received a kidney transplant from a 50 - 59 year old donor with two of the following three factors: history of hypertension, cerebrovascular accident as cause of death, final pre-procurement serum creatinine > 1.5 mg/dL (united network for organ sharing [UNOS] expanded criteria donor)

• Cold ischemia time of the donor kidney is = 30 hours

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• De Novo Kidney Transplantation

Intervention

Drug:
• Alefacept
IV and subcutaneous injection
• placebo
IV and subcutaneous injection
• Tacrolimus
The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
• Mycophenolate Mofetil
Mycophenolic mofetil was administered as 750 mg twice per day orally
• Steroids
Methylprednisolone or equivalent: Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus Prednisone or equivalent: Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Countries where clinical trial is conducted

Austria,  Belgium,  Czech Republic,  France,  Germany,  Hungary,  Italy,  Netherlands,  Poland,  Spain,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Biopsy-confirmed Acute T-cell Mediated Rejection at Month 6 Assessed by Local Review	Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification: Grade IA: significant interstitial infiltration (>25% parenchyma affected) and foci of moderate tubulitis; Grade IB: significant interstitial infiltration (>25% parenchyma affected) and foci of severe tubulitis; Grade IIA: mild to moderate intimal arteritis; Grade IIB: severe intimal arteritis comprising >25% of the luminal area; Grade III: "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocyte inflammation.; A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade = 1.; The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.	6 months	No
Secondary	Percentage of Participants With Biopsy Confirmed Antibody-Mediated Acute Rejection at Month 6	Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification: Acute antibody-mediated rejection - documented anti-donor antibody ('suspicious for' if antibody not demonstrated): Grade I: acute tubular necrosis-like - complement split product positive (C4d+), minimal inflammation; Grade II: capillary-margination and/or thromboses, C4d+; Grade III: arterial - v3, C4d+.; A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade = 1.; The Kaplan-Meier estimate of biopsy-confirmed antibody-mediated acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.	6 months	No
Secondary	Percentage of Participants With Biopsy Confirmed Acute Rejection (T-Cell Mediated or Antibody Mediated) at Month 6	Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade = 1.; The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated or antibody-mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.	6 months	No
Secondary	Percentage of Participants With Biopsy Confirmed Acute Mixed T-Cell Mediated and Antibody-Mediated Rejection at Month 6	Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade = 1.; The Kaplan-Meier estimate of biopsy-confirmed acute mixed T-cell mediated and antibody-mediated rejections within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.	6 months	No
Secondary	Percentage of Participants With Acute Rejection Diagnosed by Signs and Symptoms at Month 6	Acute rejection diagnosed by signs and symptoms, including biopsy-confirmed or suspected (not confirmed by biopsy - i.e. no biopsy was performed or biopsy did not confirm an acute T-cell mediated rejection). The Kaplan-Meier estimate of acute rejection diagnosed by signs and symptoms within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.	6 months	No
Secondary	Percentage of Participants With Clinically Treated Acute Rejection at Month 6	Patients who received immunosuppressive medications for the treatment of suspected or biopsy-confirmed acute rejections were considered to have a clinically-treated acute rejection. The Kaplan-Meier estimate of clinically treated acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.	6 months	No
Secondary	Percentage of Participants With Steroid-resistant Acute Rejection at Month 6	A steroid-resistant acute rejection is defined as a rejection episode which did not resolve following treatment with corticosteroids. In the case that a rejection episode was not treated with corticosteroids first but only with antibodies, it was included in this category.; The Kaplan-Meier estimate of steroid-resistant acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.	6 months	No
Secondary	Percentage of Participants With Biopsy-Confirmed Acute T-cell Mediated Rejection as Assessed by Central Review at Month 6	Biopsies were graded by the central reviewer according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade = 1.; The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.	6 months	No
Secondary	Patient Survival	Patient survival is any participant known to be alive at Month 6. The Kaplan-Meier estimate of patient survival within the first 6 months following transplantation is reported. Participants lost to follow-up were censored at the time of last assessment.	6 months	No
Secondary	Graft Survival	Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months. Graft loss is defined as re-transplantation, nephrectomy, death or as dialysis ongoing at end of study or at discontinuation of the participant unless superseded by follow-up information.; The Kaplan-Meier estimate of graft survival within the first 6 months following transplantation is reported. Participants lost to follow-up were censored at the time of last assessment.	6 months	No
Secondary	Maximum Histological Grade of All Biopsies After Local Review	The grade of acute rejection was classified according to Banff 97/05 updated version. If a patient had more than 1 rejection episode, the episode with the most severe grade was used.; Acute T-cell mediated rejection: Grade IA: significant interstitial infiltration (>25% parenchyma affected) and foci of moderate tubulitis; Grade IB: significant interstitial infiltration (>25% parenchyma affected) and foci of severe tubulitis; Grade IIA: mild to moderate intimal arteritis; Grade IIB: severe intimal arteritis comprising >25% of the luminal area; Grade III: "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocyte inflammation.; Acute antibody-mediated rejection: Grade I: acute tubular necrosis-like - complement split product positive (C4d+), minimal inflammation; Grade II: capillary-margination and/or thromboses, C4d+; Grade III: arterial - v3, C4d+.	6 months	No
Secondary	Percentage of Participants With Anti-Lymphocyte Antibody Therapy for Treatment of Rejection at Month 6	The Kaplan-Meier estimate of anti-lymphocyte antibody therapy for acute rejection (clinically-treated or biopsy-confirmed) within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.	6 months	No
Secondary	Change From Month 1 in Serum Creatinine		Month 1, 3, and 6	No
Secondary	Change From Month 1 in Glomerular Filtration Rate (GFR)	The GFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.	Month 1, 3, and 6	No
Secondary	Change From Month 1 in Creatinine Clearance	The creatinine clearance was calculated according to the Cockcroft-Gault formula.	Month 1, 3, and 6	No
Secondary	GFR Measured by Iothalamate Clearance at Month 6	GFR measured using the iothalamate clearance method and determined by a central laboratory.	Month 6	No
Secondary	Percentage of Participants With Efficacy Failure at Month 6	Efficacy failure is defined as death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading or lost to follow-up.; The Kaplan-Meier estimate of efficacy failure within the first 6 months following transplantation is reported.	6 months	No
Secondary	Percentage of Participants With Delayed Graft Function	Delayed graft function was defined as the requirement for dialysis within the first week post-transplant.	1 week	No
Secondary	Percentage of Participants With Treatment Failure at Month 6	Treatment failure is defined as efficacy failure (death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading, lost to follow-up) or early discontinuation of alefacept/placebo at any time (during the 12-week administration period) for any reason. The Kaplan-Meier estimate of treatment failure within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.	6 months	No
Secondary	Number of Participants With Adverse Events	Causally related was defined as adverse events (AEs) assessed by the Investigator as possibly or probably related to study drug or records where the relationship was missing.; A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: Resulted in death.; Was life-threatening.; Resulted in persistent or significant disability/incapacity.; Resulted in congenital anomaly or birth defect.; Required patient hospitalization or led to prolongation of hospitalization; Was considered a medically important event.; All rejections and any BK virus, Epstein Barr virus and/or cytomegalovirus infection had to be reported as an SAE	6 Months	No

External Links

•   Link to results on JAPIC - enter JapicCTI-R120226 in the JapicCTI-RNo. field